Navigation Links
AAP Initiates Public Relations Effort to Counter Bad Vaccine Publicity
Date:2/15/2008

National Autism Association Requests AAP Instead Focus on Removing Unnecessary Toxins From Vaccines and Providing Medical Treatments for Children with Autism

CHICAGO, Feb. 15 /PRNewswire-USNewswire/ -- The American Academy of Pediatrics (AAP) has initiated a "parent spokesperson" campaign to counter recent negative publicity surrounding toxins in vaccines, requesting parent vaccine proponents to conduct media interviews as "part of our ongoing response to media stories regarding autism and vaccines."

The negative publicity stems from long-standing reports from thousands of parents that the mercury-based vaccine preservative thimerosal contributed to their children's regressive autism. In 1999, the AAP issued a statement requesting the toxin be phased out of vaccines, but has since continued supporting its use as a preservative, even fighting against legislation in several states which would ban the poison from children's vaccines.

Although the mercury content in many vaccines on the current schedule has been reduced to trace amounts, these trace amounts are not regulated by the FDA. Large doses of mercury still remain in some vaccines, including flu shots. Other highly toxic substances including aluminum remain as well.

Parent advocates for children's health believe the AAP should direct their resources towards increasing the safety of vaccines, rather than damage-control media campaigns and attempts to censor fictional TV shows such as ABC's "Eli Stone." "Their resources are so valuable," says Rita Shreffler, parent and Executive Director of NAA. "It is my hope that the AAP will stop defending the continued use of poison in vaccines and instead direct that energy towards implementing promising medical treatments that have thus far been denied to the vast number of children diagnosed with autism. In the last several years, we have come to know that improvement and even recovery from autism is possible when children receive appropriate medical attention, yet the AAP continues to dismiss these treatments."

A growing body of scientific research including a Centers for Disease Control study from 2000 indicates a link between thimerosal exposure and several specific neurological injuries including autism. For years, Shreffler and her colleagues have requested the toxins be removed from all vaccines.

"If the AAP truly wants the best possible publicity for vaccines, they can start by discouraging the use of toxic components."

For more information, visit http://www.nationalautism.org.

CONTACT: Wendy Fournier, Portsmouth, RI, 401-835-5828

Rita Shreffler, Nixa, MO, 401-632-6452


'/>"/>
SOURCE National Autism Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. Harbinger Research Initiates Coverage on HearAtLast
7. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
8. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
9. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
10. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
Breaking Medicine Technology: